← Issue №17/ week of Oct 25, 2026/IBD

Large-scale proteomics identifies a pretreatment Crohn's disease core proteome and a dynamic signature for anti-TNF response.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD prospective cohort · n=80 · Oct 20, 2026 · Inflamm Bowel Dis · IF 4.5

Large-scale proteomics identifies a pretreatment Crohn's disease core proteome and a dynamic signature for anti-TNF response.

Basic scienceCrohn's diseasebiologicsanti-TNFbiomarker
Clinical takeawayNo clinical action yet: exploratory proteomic findings in pediatric Crohn's disease require external validation.
What it foundA three-protein panel (IRF1, NEUROG1, APOA5) predicted M12 endoscopic remission with AUROC 0.94 (95% CI 0.88-1.0).
ContextOpens a question: identifies potential early pharmacodynamic markers for anti-TNF response, which could refine monitoring if validated.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Karns R … Minar P · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues